Effects of pharmacological treatment on metabolomic alterations in animal models of depression

Juncai Pu1,2,4, Yiyun Liu2,4, Siwen Gui2, Lu Tian2, Yue Yu3, Dongfang Wang2, Xiaogang Zhong2, Weiyi Chen1,2, Xiaopeng Chen1,2, Yue Chen1,2, Xiang Chen1,2, Xue Gong1,2, Lanxiang Liu1, Wenxia Li1, Haiyang Wang1 and Peng Xie1,2,✉

© The Author(s) 2022

Numerous studies have investigated metabolite alterations resulting from pharmacological treatment in depression models although few quantitative studies explored metabolites exhibiting constant alterations. This study aimed to identify consistently dysregulated metabolites across such studies using a knowledge-base-driven approach. This study was based on 157 studies that identified an assembly of 2757 differential metabolites in the brain, blood, urine, liver, and feces samples of depression models with pharmacological medication. The use of a vote-counting approach to identify consistently upregulated and downregulated metabolites showed that serotonin, dopamine, norepinephrine, gamma-aminobutyric acid, anandamide, tryptophan, hypoxanthine, and 3-methoxyxymetamine were upregulated in the brain, while quinolinic acid, glutamic acid, 5-hydroxyindoleacetic acid, myo-inositol, lactic acid, and the kynurenine/tryptophan ratio were downregulated. Circulating levels of trimethylamine N-oxide, isoleucine, leucine, tryptophan, creatine, serotonin, valine, betaine, and low-density lipoprotein were elevated. In contrast, levels of alpha-D-glucose, lactic acid, N-acetyl glycoprotein, glutamine, beta-D-glucose, corticosterone, alanine, phenylacetylglutine, glycine, high-density lipoprotein, arachidonic acid, myo-inositol, allantoin, and taurine were decreased. Moreover, 12 metabolites in urine and nine metabolites in the liver were dysregulated after treatment. Pharmacological treatment also increased fecal levels of butyric acid, acetic acid, propionic acid, and isovaleric acid. Collectively, metabolite disturbances induced by depression were reversed by pharmacological treatment. Pharmacological medication reversed the reduction of brain neurotransmitters caused by depression, modulated disturbance of the tryptophan-kynurenine pathway and inflammatory activation, and alleviated abnormalities of amino acid metabolism, energy metabolism, lipid metabolism, and gut microbiota-derived metabolites.

Translational Psychiatry (2022) 12:175; https://doi.org/10.1038/s41398-022-01947-5

INTRODUCTION
Depression is a common mental illness characterized by low mood, diminished interest, and a reduced sense of pleasure, with an incidence of 6.4 to 10.4% [1, 2]. Depression severely reduces the quality of life of patients and decreases their life expectancy by ~10 years [3]. The global burden of disease due to depression has been increasing in recent decades and depression has become one of the leading causes of disability worldwide [4]. In 2018, the economic burden of depression in the United States alone was US$326.2 billion [5]. Despite the significant harm caused by depression, much uncertainty still exists about the complete molecular mechanism of depression, making it a major challenge to identify new antidepressants [6].

Classical antidepressants exert antidepressant properties by modulating monoaminergic targets. A recent meta-analysis concluded that all licensed antidepressants have a significant therapeutic effect in adults with acute depression [7]. Extensive research showing antidepressant properties of pharmacological treatments other than monoaminergic antidepressants, such as ketamine, adjunctive nutraceuticals, Traditional Chinese Medicine, and probiotics, has progressively attracted interest [8–12]. However, the underlying therapeutic mechanisms of classical antidepressants and other pharmacological treatments are not fully understood [13–15].

Metabolomics has been widely used to quantify metabolites in an organism or tissue and identify relationships between metabolites and physiological or pathological processes [16]. Indeed, because of its ability to elucidate metabolic alterations induced by treatments, metabolomics has become a vital tool for drug discovery [17]. With the merit of high accuracy in detecting the content of small molecules associated with depression (such as neurotransmitters, amino acids, lipids, and energy metabolites), metabolomic methods have emerged as powerful tools for exploring molecular alterations induced by pharmacological treatments in the brain or other tissues in animal models of depression [18–20]. Moreover, because metabolites are easily absorbed and can penetrate the blood–brain barrier, they are an important source for screening potential drug leads for the treatment of depression [21, 22].

Several issues have been raised for metabolomics studies investigating potential molecular mechanisms of antidepressant action. First, although extensive studies have been carried out, it
remains difficult to detect panoramic alterations of metabolites induced by pharmacological treatment in individual studies; accordingly, a systematic understanding of the neurochemical effects of these medications is still lacking. Second, the generalizability of much-published research on this issue is problematic, as experimental data are rather controversial due to small sample sizes and differences in experimental design. Faced with challenges surrounding how to systematically analyze these massive metabolomics data and a lack of accessible quantitative data [23, 24], few studies have explored the reliability and reproducibility of findings for metabolites across metabolomics studies.

Thus, the purpose of this study was to investigate metabolite changes consistently resulting from pharmacological treatment in depression models using a knowledgebase-driven approach. To this end, a vote-counting method was used to identify consistently upregulated and downregulated metabolites in the brain and peripheral tissues of animal models induced by pharmacological treatment from large-scale metabolomics studies.

MATERIALS AND METHODS

Data source

The dataset used in this study was obtained from the MENDA database. Details of the study design and procedures for data collection and annotation are described elsewhere [23]. Briefly, after screening more than 11,000 citations from literature and metabolomics databases as of March 2018, we collected relevant information from 464 studies that investigated metabolite alterations associated with depression and antidepressant treatment in human and animal models. Based on metabolomics and magnetic resonance spectroscopy techniques, a total of 5675 differential metabolites or metabolite ratios were identified.

As a result of the current study, we updated the MENDA database as follows. After screening more than 18,000 citations as of 11 August 2021, we cumulatively retrieved 2278 potentially eligible articles and then excluded 1461 full-text studies. Excluded studies are listed in Supplementary Data 1. In total, 817 clinical and preclinical studies were included in the MENDA database. From these studies, an assembly of 13,112 differential metabolite entries was manually curated.

Candidate metabolite set

For further study, we selected the candidate metabolite set according to the following steps. Only studies that aimed to identify differential metabolites resulting from pharmacological treatment in animal models of depression were included. Therefore, we excluded studies that (i) compared metabolite levels between depressed and control conditions; (ii) focused on non-pharmacological treatments, such as repetitive transcranial magnetic stimulation, electroacupuncture, or exercise therapy; (iii) explored metabolic changes after pharmacological treatment in a healthy state; or (iv) investigated metabolic characteristics associated with treatment response. Human and nonhuman primate models were also excluded. This decision was made a priori because metabolic profiles are clearly different between rodents, humans, and nonhuman primates [26]. We focused on rodent models because there was a large amount of data on brain tissues provided by rodent samples, while few studies have examined metabolic changes in the brain tissues of human or nonhuman primates. For analytical techniques, untargeted or targeted metabolomics studies that used mass spectrometry or nuclear magnetic resonance methods were included, while in vivo studies employing magnetic resonance spectroscopy techniques were excluded. Candidate metabolites in brain, blood, urine, liver, and feces samples were selected for analysis, whereas other tissues were excluded due to a limited amount of data.

Analytic strategy

In this study, we used the vote-counting method to identify metabolites consistently upregulated or downregulated in the candidate metabolite set. Although combining effect sizes has been the mainstream method for integrating multiple clinical metabolomics studies [27–29], meta-analyses cannot be performed because of the significant loss of quantitative data (mean concentrations and standard deviation) in the evaluated animal studies. Alternatively, the advantage of the vote-counting method is that it avoids problems associated with a lack of statistical data. Currently, it is the most feasible method for merging such a large number of studies because differential metabolites were described in most studies. Moreover, vote counting is an effective method for selecting molecules to be independently validated by external studies, with the assumption that a reliable differential molecule is robust enough to show effects across multiple studies [30]. This approach has been recently implemented in other research integrating large-scale metabolomics studies [31, 32].

In the current study, the following analyses were performed based on the vote-counting procedure. In the primary analysis, we analyzed metabolite alterations in brain, blood, urine, liver, and feces samples of animal models resulting from all available pharmacological treatments. Next, secondary analyses were performed based on tissue types and pharmacological treatments. For the types of tissues, we analyzed candidate metabolites in the hippocampus, prefrontal cortex, hypothalamus, plasma, and serum samples. For the types of pharmacological treatments, eight licensed drugs for depression (citalopram, fluoxetine, paroxetine, venlafaxine, amitriptyline, desipramine, imipramine, and vortioxetine) were classified as antidepressants [7], and pharmacological treatments other than these licensed antidepressants (various types of compounds and Traditional Chinese Medicine) were classified as non-antidepressants. In addition, probiotics and fecal microbiota transplantation were classified as non-antidepressant therapy because they yield antidepressant effects by ameliorating metabolic disturbances and modifying the colonic ecosystem [33].

Statistical analysis

The vote-counting method is based on the hypothesis that the probability of upregulation or downregulation of a differential metabolite follows a binomial distribution, i.e., there is a random occurrence of significant upregulation or downregulation for the altered metabolite in each study. In this study, we calculated the vote-counting statistic (VCS) for each metabolite in the vote-counting procedure. Each metabolite entry exhibiting an upregulation or downregulation trend was scored with 1 or −1 points, respectively. Next, the VCS for each metabolite was calculated by computing the total score of all studies, with VCS values more than 0 indicating that the candidate metabolite was predisposed to be upregulated across studies, and vice versa. Duplicate metabolites curated from the same study but with different study designs (including different types of drugs, dose groups, types of tissues, and analytical techniques) were considered to be derived from independent studies. For each metabolite, the one-tailed P value of the binomial test was estimated to compare hypothesized versus obtained counts of upregulation and downregulation trends, using the binom.test function in R version 4.0.4 (https://www.R-project.org/). A P value < 0.05 was considered statistically significant. Metabolites with total counts of dysregulation less than four were not introduced into the vote-counting procedures because their minimum P values were 0.125.

RESULTS

Data sets

After data selection, we excluded 660 studies from the MENDA database (listed in Supplementary Data 2). At the metabolite level, we excluded 10,355 differential metabolite entries from the 13,112 metabolite entries. The reasons for these excluded studies and metabolite entries are summarized in Supplementary Table 1. Detailed information of the 157 studies and 2757 metabolite entries used in the current study are presented in Supplementary Data 3 and Supplementary Data 4, respectively. Next, metabolic alterations in the brain, blood, urine, liver, and feces were investigated by vote-counting procedures based on the candidate metabolite set. The numbers of studies and metabolite entries for each tissue are summarized in Supplementary Table 2.

Effects of pharmacological treatment on metabolite alterations in the brain

Among 46 metabolites and one metabolite ratio that were voted in the brain, eight and six were consistently upregulated and downregulated, respectively (Fig. 1A). Specifically, serotonin (VCS = 47, P < 0.001), dopamine (VCS = 41, P < 0.001),
Among the six candidate metabolites evaluated in the hypothalamus are shown in Fig. 1B. Only serotonin, dopamine, and GABA metabolites in the hippocampus, prefrontal cortex, and hypothalamus (Supplementary Table 6). Numbers of shared dysregulated metabolites were consistently dysregulated (Fig. 2A). Specifically, concentrations of serotonin (VCS = 23, P < 0.001), GABA (VCS = 17, P < 0.001), norepinephrine (VCS = 13, P < 0.001), dopamine (VCS = 12, P < 0.001), glycine (VCS = 7, P = 0.008), and hypoxanthine (VCS = 7, P = 0.008) were increased, whereas concentrations of glutamic acid (VCS = 9, P = 0.047), myo-inositol (VCS = 8, P = 0.004), and lactic acid (VCS = 5, P = 0.031) were decreased (Supplementary Table 3).

We further analyzed metabolite alterations in the hippocampus (504 metabolite entries), prefrontal cortex (164 metabolite entries), and hypothalamus (39 metabolite entries). Of the 28 candidate metabolites in the hippocampus, six were upregulated and three were downregulated. Specifically, concentrations of serotonin (VCS = 23, P < 0.001), GABA (VCS = 17, P < 0.001), norepinephrine (VCS = 13, P < 0.001), dopamine (VCS = 12, P < 0.001), and myo-inositol (VCS = 5, P = 0.031) were downregulated. Specifically, trimethylamine N-oxide (VCS = 28, P < 0.001), isoleucine (VCS = 21, P < 0.001), creatine (VCS = 13, P = 0.002), leucine (VCS = 13, P < 0.001), pyruvic acid (VCS = 10, P = 0.001), betaine (VCS = 7, P = 0.020), valine (VCS = 7, P = 0.008), and serotonin (VCS = 7, P = 0.008) were upregulated, and N-acetyl glycoprotein (VCS = 22, P < 0.001), alpha-D-glucose (VCS = −21, P < 0.001), lactic acid (VCS = −21, P < 0.001), and glutamine (VCS = −10, P = 0.001) were downregulated (Supplementary Table 3).

Effects of pharmacological treatment on metabolite alterations in blood

The results of vote counting showed that 23 of the 63 circulating metabolites were consistently dysregulated (Fig. 2A). Specifically, levels of trimethylamine N-oxide (VCS = 29, P < 0.001), isoleucine (VCS = 21, P < 0.001), leucine (VCS = 16, P < 0.001), tryptophan (VCS = 12, P = 0.004), creatine (VCS = 11, P = 0.022), serotonin (VCS = 10, P = 0.006), valine (VCS = 9, P = 0.006), betaine (VCS = 8, P = 0.011), and low-density lipoprotein (LDL; VCS = 6, P = 0.016) were upregulated, while levels of alpha-D-glucose (VCS = −25, P < 0.001), lactic acid (VCS = −23, P < 0.001), N-acetyl glycoprotein (VCS = −18, P < 0.001), glutamine (VCS = −15, P < 0.001), beta- D-glucose (VCS = −11, P < 0.001), corticosterone (VCS = −11, P < 0.001), alanine (VCS = −9, P = 0.018), phenylacetylglutamine (VCS = −9, P = 0.02), glycine (VCS = −8, P = 0.011), high-density lipoprotein (HDL; VCS = −8, P = 0.004), arachidonic acid (VCS = −7, P = 0.046), myo-inositol (VCS = −7, P = 0.008), allantoin (VCS = −5, P = 0.031), and taurine (VCS = −5, P = 0.031) were downregulated (Supplementary Table 3).

We further analyzed metabolite alterations in plasma (344 metabolite entries) and serum samples (663 metabolite entries). Among the 29 candidate metabolites in plasma, six were upregulated and three were downregulated. Specifically, tryptophan (VCS = −10, P = 0.001) was increased, and concentrations of corticosterone (VCS = −11, P < 0.001), arachidonic acid (VCS = −7, P = 0.008), glycine (VCS = −6, P = 0.035), D-glucose (VCS = −5, P = 0.031), and glutamine (VCS = −5, P = 0.031) were decreased (Supplementary Table 8). Eighteen of the 43 candidate metabolites in serum were dysregulated. Specifically, trimethylamine N-oxide (VCS = 28, P < 0.001), isoleucine (VCS = 21, P < 0.001), creatine (VCS = 13, P = 0.002), leucine (VCS = 13, P < 0.001), pyruvic acid (VCS = 10, P = 0.001), betaine (VCS = 7, P = 0.020), valine (VCS = 7, P = 0.008), and serotonin (VCS = 7, P = 0.008) were upregulated, and N-acetyl glycoprotein (VCS = −22, P < 0.001), alpha-D-glucose (VCS = −21, P < 0.001), lactic acid (VCS = −21, P < 0.001), and glutamine (VCS = −10, P = 0.001) were downregulated (Supplementary Table 7). Eighteen of the 43 candidate metabolites in serum were dysregulated. Specifically, trimethylamine N-oxide (VCS = 28, P < 0.001), isoleucine (VCS = 21, P < 0.001), creatine (VCS = 13, P = 0.002), leucine (VCS = 13, P < 0.001), pyruvic acid (VCS = 10, P = 0.001), betaine (VCS = 7, P = 0.020), valine (VCS = 7, P = 0.008), and serotonin (VCS = 7, P = 0.008) were upregulated, and N-acetyl glycoprotein (VCS = −22, P < 0.001), alpha-D-glucose (VCS = −21, P < 0.001), lactic acid (VCS = −21, P < 0.001), and glutamine (VCS = −10, P = 0.001) were downregulated (Supplementary Table 8).

Effects of pharmacological treatment on metabolite alterations in urine

The results of vote counting showed that 12 of the 33 candidate metabolites in urine were dysregulated (Fig. 3A). Specifically, levels of oxoglutaric acid (VCS = 12, P < 0.001), acetic acid (VCS = 10, P = 0.001), creatinine (VCS = 9, P = 0.011), betaine (VCS = 8, P = 0.004), phenylacetylglutamine (VCS = 6, P = 0.016), xanthurenic...
depression models [31]. An overview of consistently dysregulated metabolites in the brain, blood, and urine samples of compared the current data with our previous data showing depression can be reversed by pharmacological treatment, we To further explore which metabolite disturbances induced by depression induced by depression (Table 12). Of the 18 candidate metabolites that were voted in the liver, one alterations in the liver Effects of pharmacological treatment on metabolite alterations in the blood of depression models. A Volcano plot for consistently upregulated (red) and downregulated (blue) metabolites across studies. The vote-counting statistic (VCS) is presented on the x-axis and the −log10 (p value) is presented on the y-axis. B Venn plot for shared dysregulated metabolites between blood, serum, and plasma. HDL high-density lipoprotein, LDL low-density lipoprotein.

acid (VCS = 6, P = 0.035), creatine (VCS = 5, P = 0.031), indoleacetic acid (VCS = 5, P = 0.031), and tryptophan (VCS = 5, P = 0.031) were increased, while levels of glycine (VCS = −7, P = 0.008), cortisol (VCS = −6, P = 0.016), and glutamine (VCS = −5, P = 0.031) were decreased (Supplementary Table 10).

Effects of pharmacological treatment on metabolite alterations in the liver
Of the 18 candidate metabolites that were voted in the liver, one was consistently upregulated and eight were consistently downregulated (Fig. 3B). Specifically, the concentration of ornithine (VCS = −6, P = 0.016) was increased, while concentrations of beta- D-glucose (VCS = −8, P = 0.004), lactic acid (VCS = −8, P = 0.011), arachidonic acid (VCS = −7, P = 0.008), alpha-D-glucose (VCS = −6, P = 0.016), tryptophan (VCS = −6, P = 0.016), 3′-AMP (VCS = −5, P = 0.031), creatine (VCS = −5, P = 0.031), and tyrosine (VCS = −5, P = 0.031) were decreased (Supplementary Table 11).

Effects of pharmacological treatment on metabolite alterations in feces
Of the five candidate metabolites in feces, four were consistently upregulated, including butyric acid (VCS = 8, P = 0.011), acetic acid (VCS = 7, P = 0.008), propionic acid (VCS = 7, P = 0.033), and isovaleric acid (VCS = 5, P = 0.031) (Fig. 3C and Supplementary Table 12).

Pharmacological treatment reversed metabolite disturbances induced by depression
To further explore which metabolite disturbances induced by depression can be reversed by pharmacological treatment, we compared the current data with our previous data showing dysregulated metabolites in the brain, blood, and urine samples of depression models [31]. An overview of consistently dysregulated metabolites resulting from depression and pharmacological treatment in animal models is shown in Fig. 4.

Among the 11 dysregulated metabolites in the brains of depression models, eight were reversed by pharmacological treatment (Fig. 4A). Specifically, decreased levels of serotonin, dopamine, norepinephrine, GABA, anandamide, and tryptophan, as well as increased levels of myo-inositol and the kynurenine/tryptophan ratio resulting from depression were reversed following treatment. However, increased levels of kynurenic acid and oxo-kynurenine and the decreased level of N-acetyl-L-aspartic acid were not attenuated following treatment.

For metabolite disturbances in blood, pharmacological treatment reversed eight of the 12 dysregulated metabolites, including decreased concentrations of serotonin, tryptophan, leucine, valine, and trimethylamine N-oxide, as well as increased concentrations of N-acetyl glycoprotein, corticosterone, and glutamine (Fig. 4B). Decreased concentrations of tyrosine, proline, oleamide, and pyruvic acid were not reversed following treatment.

Among the ten dysregulated metabolites resulting from depression in urine, only four downregulated metabolites (tryptophan, creatine, betaine, and oxoglutaric acid) were reversed by pharmacological treatment (Fig. 4C). Dysregulated levels of L-DOPA, palmitic acid, pimelic acid, citric acid, proline, and hippuric acid were not attenuated following treatment.

Effects of antidepressants and non-antidepressants on metabolite alterations
We further explored the commonalities and differences of metabolic effects resulting from antidepressants and non-antidepressants. For metabolites in the brain, a total of 344 and 555 metabolite entries resulting from antidepressants and non-antidepressants were voted, respectively. Of the 15 candidate metabolites of antidepressants, six were dysregulated (Supplementary Table 13). For non-antidepressants, seven of the 26 candidate metabolites were dysregulated (Supplementary Table 14). These altered metabolites are summarized in Fig. 5A. Notably, levels of dopamine, norepinephrine, and GABA were upregulated by both antidepressants and non-antidepressants. In addition, concentrations of tryptophan, 5-hydroxyindoleacetic acid, and quinolinic acid were altered by antidepressants, while concentrations of serotonin, anandamide, hypoxanthine, and myo-inositol were altered by non-antidepressants.
For metabolites in blood, a total of 289 and 718 metabolite entries assessing antidepressants and non-antidepressants were voted, respectively. Among 17 candidate metabolites assessing antidepressants, five were dysregulated (Supplementary Table 15). For non-antidepressants, 18 of the 48 candidate metabolites were dysregulated (Supplementary Table 16). Levels of trimethylamine N-oxide and leucine were upregulated by both antidepressants and non-antidepressants, while lactic acid and glutamine were downregulated (Fig. 5B). The concentration of tryptophan was altered by antidepressants, while concentrations of isoleucine, creatine, serotonin, valine, N-acetyl glycoprotein, myo-inositol, glycine, HDL, alanine, phenylacetylglucine, alpha-D-glucose, beta-D-glucose, and corticosterone were altered by non-antidepressants.

We next investigated metabolite alterations in urine, liver, and feces. Neither of the two candidate metabolites potentially altered by antidepressants in urine were significantly dysregulated (Supplementary Table 17). Moreover, no candidate metabolites in the liver or feces were voted due to limited numbers of metabolite entries. For non-antidepressants, six candidate metabolites (oxoglutaric acid, acetic acid, betaine, phenylacetylglycine, creatinine, and glycine) were dysregulated in urine (Fig. 5C and Supplementary Table 18), four candidate metabolites (alpha-D-glucose, beta-D-glucose, lactic acid, and arachidonic acid) were decreased in the liver (Fig. 5D and Supplementary Table 19), and two candidate metabolites (acetic acid and butyric acid) were increased in feces (Fig. 5E and Supplementary Table 20).

**DISCUSSION**

Although numerous studies have assessed the effects of pharmacological treatment on metabolite levels in depression models, inconsistent results for dysregulation of metabolites were reported. Here, we performed the first systematic investigation to identify consistently dysregulated metabolites using a knowledgebase-driven approach. The results of vote-counting procedures showed that 13 metabolites and one metabolite ratio in the brain, 23 metabolites in blood, 12 metabolites in urine, nine metabolites in the liver, and four metabolites in feces were consistently dysregulated across the evaluated large-scale studies. These findings represent the panoramic metabolomic alterations induced by pharmacological treatment in depression, thus contributing to an understanding of the molecular mechanisms underlying antidepressant effects.

Consistent with our expectations, we confirmed that the regulatory effect of neurotransmitters is the most pronounced feature of brain metabolite alterations caused by pharmacological treatment. In fact, we found that these treatments reversed decreased brain levels of monoamine neurotransmitters, GABA, and anandamide caused by depression. For monoamine neurotransmitters, pharmacological treatment increased serotonin levels and decreased levels of its main metabolite 5-hydroxyindoleacetic acid, increased concentrations of dopamine and its metabolite 3-methoxytyramine, and upregulated norepinephrine levels. These findings are consistent with the neurochemical mechanism of classic antidepressants [34]. We also found that pharmacological medication promoted the synthesis of GABA and reduced the content of its precursor glutamic acid. However, human studies investigating alterations of glutamatergic metabolite levels after treatment reported inconsistent results. Previous magnetic resonance spectroscopy studies reported that both decreased glutamic acid levels and increased GABA levels in the cingulate were associated with reduced depressive symptoms in patients with major depressive disorder (MDD) following citalopram treatment [35, 36]. Another study found that cortical concentrations of these metabolites were not altered after escitalopram treatment [37]. We also found reduced glutamine levels in blood and urine following treatment, but discordant results were reported in patients with MDD [38, 39]. Therefore, further studies with larger sample sizes are needed to investigate alterations of glutamatergic metabolites induced by antidepressant treatment. We also found that pharmacological treatment increased anandamide levels in the brain. Consistent with our results, a preclinical study showed that anandamide exerted antidepressant effects by antagonizing the cannabinoid CB1 receptor [40].

Our results show that pharmacological treatment reduced corticosterone levels in blood and cortisol levels in urine. In rodents, cortisol and corticosterone are endogenous glucocorticoids induced by stressful conditions through activation of the hypothalamic-pituitary-adrenal (HPA) axis [41], disturbance of which have been implicated in the pathophysiology of depression [42]. In line with our results, preclinical and clinical evidence show that modulating the function of the HPA axis is a potential treatment approach for depression [43]. Therefore, the results of this study support the notion that pharmacological medications exert antidepressant effects by alleviating activation of the HPA axis.
In this study, we found that pharmacological treatment increased central and circulating levels of tryptophan, while brain levels of quinolinic acid, kynurenine, and the kynurenine/tryptophan ratio showed a decreasing trend or statistically significant decrease. Tryptophan and its two metabolites (indo-5-methyl-D-aspartate receptor to exert antidepressant effects by modulating disturbances of the tryptophan-kynurenine pathway and alleviating inflammatory activation.

Another important finding was that pharmacological treatment modulated microbiota-derived metabolites. We found that the levels of four short-chain fatty acids (SCFAs), including acetic acid, butyric acid, isovaleric acid, and propionic acid, were increased in feces and urine following treatment. SCFAs are mainly derived from dietary fiber and maintain the function of the innate gut barrier [51]. Preclinical evidence shows that supplementation with an SCFA mixture could counteract the depressive behavior caused by chronic stress [52]. Clinical evidence also demonstrated that fecal levels of SCFAs were negatively correlated with depression scale scores [53]. Therefore, pharmacological treatment may exert antidepressant effects by modulating SCFA-producing bacteria. We also found that blood and urine levels of betaine, which is derived from dietary choline, were increased following treatment [54]. Interestingly, a recent study showed that betaine supplementation in mice could lead to stress resilience accompanied by alleviated elevation of fecal SCFAs and release of circulating interleukin 6 [55]. Trimethylamine N-Oxide is a gut-microbe-derived metabolite produced from dietary choline and carnitine [56]. In the current study, we found that pharmacological treatment alleviated the reduction of trimethylamine N-Oxide in the blood of depression models, suggesting that these treatments...
Fig. 5  Effects of antidepressants and non-antidepressants on metabolite alterations. Metabolite changes resulting from antidepressants and non-antidepressants in the brain (A), blood (B), urine (C), liver (D), and feces (E). Red plus and green minus signs in the diagram indicate significant upregulation and downregulation, respectively.
could improve nutritional status and modulate gut microbiota. Phenylacetylglucose, a metabolite transformed from dietary phenylalanine that acts on adrenergic receptors, has been implicated in platelet hyperresponsiveness [57]. Interestingly, previous studies demonstrated that stress could lead to a prothrombotic state, which could be attenuated by antidepressants [58, 59]. We found that concentrations of phenylacetylglucose were decreased following treatment, suggesting that these treatments may also affect phenylacetylglucose synthesis to alleviate prothrombotic states by modulating gut microbiota.

The results of vote counting suggest that pharmacological treatment improved abnormalities of amino acid metabolism in animal models of depression. Branched-chain amino acids, including leucine, isoleucine, and valine, play important roles in promoting protein synthesis [60]. We found that pharmacological treatment elevated blood levels of these three branched-chain amino acids in this study, consistent with our previous finding that circulating levels of leucine were decreased in both patients with MDD and depression models, implicating a chronic catabolic state in depression [27, 31]. In addition, we found that ornithine was the only upregulated metabolite in the liver. Ornithine is synthesized as an intermediate metabolite in the urea cycle, which disposes excess nitrogen by converting ammonia to urea [61]. Collectively, this evidence suggests that pharmacological treatment could promote protein synthesis and improve disturbances of nitrogen metabolism.

We found that pharmacological medications modulated energy metabolism in animal models of depression. The results of vote counting showed that pharmacological treatment reduced blood glucose levels and alleviated the accumulation of lactic acid in the brain and periphery. One possible reason for this observation is that stress conditions in animal models promoted insulin resistance and mobilized glucose [62], which were reversed by pharmacological treatment. Moreover, circulating levels of two energy metabolites, oxoglutaric acid, and creatine, were elevated after treatment. Oxoglutaric acid, also known as alpha-ketoglutarate, is an intermediate in the citric acid cycle [63]. Creatine is synthesized in the liver and transported throughout the body to facilitate the recycling of adenosine triphosphate, and creatine supplementation exerted antidepressant effects in mice [64, 65]. Therefore, these results implicate improvements in energy dyshomeostasis in the molecular mechanism of pharmacological treatments of depression.

Our findings also suggest that pharmacological medication improved peripheral lipid abnormalities in depression models. Following treatment, LDL levels were elevated and HDL levels were reduced in blood. A previous study demonstrated that antidepressant therapy decreased blood LDL levels without affecting HDL levels [66], while another study found that patients with MDD presenting with and without metabolic syndrome showed different trends for these metabolic parameters after antidepressant treatment [67]. A previous study with 2461 participants also showed that patients with different MDD subtypes had distinct blood lipid profiles [68]. Therefore, more studies are still needed to explore baseline levels and post-treatment changes in LDL and HDL cholesterol in the context of depression. We also found that levels of arachidonic acid, an essential omega-6 fatty acid, were decreased in the blood and liver. Clinical studies previously found that the reduction of arachidonic acid in blood was associated with antidepressant treatment response [69]. Moreover, because arachidonic acid is a precursor of pro-inflammatory eicosanoids, its reduction suggests abrogation of the inflammatory response in depression [70].

Finally, the present study compared metabolic changes associated with different pharmacological treatments in depression models. The results of vote-counting procedures showed that both antidepressants and non-antidepressants modulated levels of monoamine neurotransmitters and GABA in the brain. However, the regulatory effect of antidepressants on anandamide was unclear. Moreover, we found that antidepressants increased central and peripheral levels of tryptophan, while non-antidepressants did not show similar effects. Notably, we found that most of the dysregulated metabolites in the blood resulting from antidepressants were also altered by non-antidepressants, suggesting a significant overlap in the metabolic changes elicited by antidepressants and non-antidepressants, although the latter caused more diverse molecular changes. Despite these findings, more studies are needed to further verify our results.

LIMITATIONS

There are some limitations to this study. First, we could not identify dysregulated metabolites other than the candidate metabolites due to the shortcomings of the vote-counting method. Second, although more comprehensive statistical results could be provided by merging raw data or combining mean concentrations of the candidate metabolites, this remains a difficult task to complete. In addition, it is difficult to compare metabolic changes brought about by different types of pharmacological treatments, such as fluoxetine and venlafaxine, due to the limited number of metabolite entries.

CONCLUSIONS

We present a systematic characterization of metabolomic alterations resulting from pharmacological treatment in depression models, which contributes to the understanding of the molecular mechanism of antidepressant effects. The results of vote-counting procedures suggested that pharmacological medications reversed the reduction of brain neurotransmitter levels caused by depression, modulated disturbance of the tryptophan-kynurenine pathway and inflammatory activation, and alleviated abnormalities of amino acid, energy, and lipid metabolism. Pharmacological treatment reversed metabolite disturbances induced by depression, however further studies with more metabolite entries are needed to verify our results.

REFERENCES

1. Arias-de la Torre J, Vilagut G, Ronaldson A, Serrano-Blanco A, Martín V, Peters M, et al. Prevalence and variability of current depressive disorder in 27 European countries: a population-based study. Lancet Public Health. 2021;6:e729–38.
2. Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75:336–46.
3. Das-Munshi J, Chang CK, Dregan A, Hatch SL, Morgan C, Thornicroft G, et al. How do ethnicity and deprivation impact on life expectancy at birth in people with serious mental illness? Observational study in the UK. Psychol Med. 2021;51:2581–9.
4. Greenberg PE, Fournier AA, Siitsky T, Simes M, Berman R, Koenigsberg SH, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2014). Pharmacoeconomics. 2021;39:653–65.
5. Rehm J, Shield KD. Global burden of disease and the impact of mental and addictive disorders. Curr Psychiatry Rep. 2019;21:10.
6. Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017;4:409–18.
7. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391:1357–66.
8. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Chaney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–4.
9. Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, et al. Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. Am J Psychiatry. 2016;173:575–87.
10. Wang Y, Fan R, Huang X. Meta-analysis of the clinical effectiveness of traditional Chinese medicine formula Chaihu-Shugan-San in depression. J Ethnopharmacol. 2012;141:571–7.
28. Pu J, Liu Y, Zhang H, Tian L, Gui S, Yu Y, et al. An integrated meta-analysis of Guasch-Ferré M, Hruby A, Toledo E, Clish CB, Martínez-González MA, Salas-Salavador J, Getseiler D, Ziv O, Ronen O, Reuveni E, Koren O, et al. Antidepressants affect gut microbiota and Ruminococcus flavefaciens is able to abolish their effects on depressive-like behavior. Transl Psychiatry. 2019:133.

32. Pu J, Yu Y, Liu Y, Tian L, Gui S, Song X, et al. Metabolomic changes in animal models. Mol Psychiatry. 2017;22:656–65.

35. Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology. 2002;27(6):949–59.

36. Smith GS, Oeltzschner G, Gould NF, Leoutsakos JS, Nassery N, Joo JH, et al. Neurotransmitters and neurometabolites in late-life depression: a preliminary magnetic resonance spectroscopy study at 7T. J Affect Disord. 2021;279:417–25.

37. Brennan BP, Admon R, Perrelli C, Laffamme EM, Athey AJ, Pizzagalli DA, et al. Acute change in anterior cingulate cortex GABA, but not glutamine/glutamate, mediates antidepressant response to citalopram. Psychiatry Res Neuroimaging. 2017;269:1–6.

38. Godlewiska BR, Narrow J, Cowen PJ. Neurochemistry of major depression: a study using magnetic resonance spectroscopy. Psychopharmacology. 2015;232:501–7.

39. Umehara H, Numata S, Watanabe SY, Hatakeyama Y, Kondo T, Tomioka Y, et al. Altered KYN/TRP, Glu/Glu, and Met/methionine sulfoxide ratios in the blood plasma of medication-free patients with major depressive disorder. Sci Rep. 2017;7:4855.

40. Kucharová-Braginová E, Saygin MZ, Caliçman S, Kaplan OK, Unsal C, Gören MZ. The change in plasma GABA, glutamine and glutamate levels in fluoxetine- and citalopram-treated female patients with major depression. Eur J Clin Pharmacol. 2019;75:571–7.

41. de Morais H, de Souza CP, da Silva LM, Ferreira DM, Baggio CH, Vanossen AC, et al. Anandamide reverses depressive-like behavior, neurochemical abnormalities and oxidative-stress parameters in streptozotocin-diabetic rats: Role of CB1 receptors. Eur Neuropsychopharmacol. 2016;26:1590–600.

42. Gong S, Miao YL, Jiao GZ, Sun MJ, Li H, Li J, et al. Dynamics and correlation of serum cortisol and corticosterone under different physiological or stressful conditions or in stress model. PLoS ONE. 2015;10:e0117503.

43. Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. Annu Rev Pharmacol Toxicol. 2010;50:1035–56.

44. Dwyer JY, Aftab A, Badgaiyan R, Widge A, Rodriguez CI, Carpenter LL, et al. Hormonal treatments for major depressive disorder: state of the art. Am J Psychiatry. 2020;177:676–705.

45. Marx W, McGuinness AJ, Rocks T, Rauschen A, O'Donovan M, et al. Metabolomics profile in depression: a pooled analysis of 230 metabolic markers in 5283 cases with depression and 10,145 controls. Biol Psychiatry. 2020;87:409–18.

46. Haris M, Cai K, Singh A, Hariharan H, Reddy R. In vivo mapping of brain myo-inositol. Neuroimage. 2011;54:802–10.

47. Kim SY, Choi CB, Lee HS, Lee SH, Woo DC, Kim HY, et al. Reversal of myo-inositol metabolic level in the left dorsolateral prefrontal cortex of rats exposed to forced swimming test following desipramine treatment: an in vivo localized (1)H-MRS study at 4.7 T. Magn Reson Imaging. 2010;28:1461–7.

48. Kraikvader KA, Fan J, Bäckhed F. Gut microbial metabolites as multi-kingsdom intermediates. Nat Rev Microbiol. 2021;19:477–94.

49. de Wouters M, Boehme M, Lyte MJ, Wiley N, Strain C, O'Sullivan O, et al. Short-chain fatty acids: microbial metabolites that alleviate stress-induced brain-gut axis alterations. J Proteome. 2018;586:4923–44.

50. Skonieczna-Zydecka K, Grochans E, Maciejewski D, Szkup M, Schneider-Matyka D, Jurczak A, et al. Faecal short chain fatty acids profile in depression: a randomised, controlled trial in postmenopausal women. Br J Nutr. 2012;108:1264–71.

51. Qu Y, Zhang K, Pu Y, Chang L, Wang S, Tan Y, et al. Altered KYN/TRP, Gln/Glu, and Met/methionine sulfoxide ratios in the blood plasma of medication-free patients with major depressive disorder. Eur J Clin Pharmacol. 2020;76:4923–44.

52. Wallace JM, McCormack JM, McNulty H, Walsh PM, Robson PJ, Bonham MP, et al. Choline supplementation and measures of choline and betaine status: a randomised, controlled trial in postmenopausal women. Br J Nutr. 2012;108:1264–71.

53. Yu Y, Zhang K, Pu Y, Chang L, Wang S, Tan Y, et al. Betaine supplementation is associated with the resilience in mice after chronic social defeat stress; a role of brain-gut-microbiota axis. J Affect Disord. 2020;272:66–76.

54. Wang Z, Bergeron N, Levison BS, Li XS, Chiu S, Jia X, et al. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. Mol Psychiatry. 2021;26:1590–78.

55. Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012:79:1356–65.

56. Brown SJ, Huang XF, Newell KA. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. Mol Psychiatry. 2021;26:1590–78.

57. Wörheide MA, Krumsiek J, Kastenmüller G, Arnold M. Multi-omics integration in biological research. Nat Prod Rep. 2016;33:1028–40.
60. Leo R, Di Lorenzo G, Tesauro M, Razzini C, Forleo GB, Chiricolo G, et al. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry. 2006;67:1760–6.
61. White PJ, Newgard CB. Branched-chain amino acids in disease. Science. 2019;363:582–3.
62. Sivashanmugam M, Jaidev J, Umashankar V, Sulochana KN. Ornithine and its role in metabolic diseases: an appraisal. Biomed Pharmacother. 2017;86:185–94.
63. Gold PW. The organization of the stress system and its dysregulation in depressive illness. Mol Psychiatry. 2015;20:32–47.
64. Huergo LF, Dixon R. The emergence of 2-oxoglutarate as a master regulator metabolite. Microbiol Mol Biol Rev. 2015;79:419–35.
65. Kazak L, Cohen P. Creatine metabolism: energy homeostasis, immunity and cancer biology. Nat Rev Endocrinol. 2020;16:421–36.
66. Pazini FL, Cunha MP, Rosa JM, Colla AR, Lieberknecht V, Oliveira Á, et al. Creatine, similar to ketamine, counteracts depressive-like behavior induced by corticosterone via PI3K/Akt/mTOR pathway. Mol Neurobiol. 2016;53:6818–34.
67. Pan SJ, Tan YL, Yao SW, Xin Y, Yang X, Liu J, et al. Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression. Acta Pharmacol Sin. 2018;39:1463–72.
68. Paslakis G, Gilles M, Lederbogen F, Schilling C, Scharnholz B, Deuschle M. The effect of a 4-week treatment with reboxetine on metabolic parameters of depressed inpatients. Eur Arch Psychiatry Clin Neurosci. 2011;261:173–7.
69. van Reedt Dortland AK, Giltay EJ, van Veen T, van Pelt J, Zitman FG, Penninx BW. Associations between serum lipids and major depressive disorder: results from the Netherlands Study of Depression and Anxiety (NESDA). J Clin Psychiatry. 2010;71:729–36.
70. Mocking RJT, Nap TS, Westerink AM, Assies J, Vaz FM, Koeter MWJ, et al. Biological profiling of prospective antidepressant response in major depressive disorder: associations with (neuro)inflammation, fatty acid metabolism, and amygdala-reactivity. Psychoneuroendocrinology. 2017;79:94–92.

ACKNOWLEDGEMENTS

We thank Liwen Bianji (Edanz) (www.liwenbianji.cn/) for basic language editing of a draft of this manuscript. This work was supported by the National Key Research and Development Program of China (Grant no. 2017YFA0505700), the Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences (Grant no. 2019PT320002), the Natural Science Foundation Project of China (Grant no. 81820108015 and 82101596), the Young Elite Scientists Sponsorship Program by CAST (Grant no. 2021QNPC01), and the China Postdoctoral Science Foundation (Grant no. 2021M6703926, 2021MD693926, 2020TQ0393, and 2020M683634X).

AUTHOR CONTRIBUTIONS

Concept, design, and supervision of the study: PX and JP. Data collection: JP, YL, SG, LT, YY, DW, XZ, WC, YC, XC, XG, LL, WL, and HW. Data analysis: JP and YL. Drafting display items: JP, YL, and SG. Drafting manuscript: JP and XP. All authors read and approved the final version of the manuscript.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41398-022-01947-5.

Correspondence and requests for materials should be addressed to Peng Xie.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.